Get the Stockscreener App
115.02
0.51%
-0.59
After Hours:
114.00
-1.02
-0.89%
Novartis Ag Adr stock is traded at $115.02, with a volume of 1.18M.
It is down -0.51% in the last 24 hours and down -4.86% over the past month.
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
See More
Previous Close:
$115.61
Open:
$115.42
24h Volume:
1.18M
Relative Volume:
1.00
Market Cap:
$232.87B
Revenue:
$48.86B
Net Income/Loss:
$16.18B
P/E Ratio:
30.92
EPS:
3.72
Net Cash Flow:
$11.72B
1W Performance:
-1.16%
1M Performance:
-4.86%
6M Performance:
+18.91%
1Y Performance:
+12.92%
1-Day Range:
$114.82
$115.50
1-Week Range:
$114.82
$116.94
52-Week Range:
$92.19
$120.92
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
| Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-05-22 | Upgrade | Stifel | Hold → Buy |
| Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
| Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-22-21 | Initiated | Bernstein | Mkt Perform |
| Mar-10-21 | Downgrade | Argus | Buy → Hold |
| Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Sep-10-20 | Upgrade | UBS | Neutral → Buy |
| Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
| Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
| May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
| May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jan-25-18 | Reiterated | Leerink Partners | Outperform |
| Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-term Growth - Morningstar
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players - Benzinga
Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors - GlobeNewswire Inc.
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years - Benzinga
Novartis Wins FDA Approval Of Kisqali For Early Breast Cancer - Barchart
Novartis' Kisqali Lowers Risk Of Breast Cancer Recurrence By 28% - Barchart
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer - GlobeNewswire Inc.
Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR - GlobeNewswire Inc.
Weekly Upgrades and Downgrades - InvestorPlace
Weekly Upgrades and Downgrades - MSN
Bipolar Disorder Market Size to Reach USD 7 Billion by 2033, Says The Brainy Insights - GlobeNewswire Inc.
Top investors say Novartis AG ADR (NVS) ticks everything they need - SETE News
Global Buccal Drug Delivery Systems Market Research 2024-2030 Featuring Johnson & Johnson, Pfizer, Sanofi, Novartis, Bayer, Teva Pharmaceuticals, AbbVie, Cipla, and Haleon - GlobeNewswire Inc.
Novartis lower as BofA downgrades on risks to valuation - MSN
$12.5 Bn Influenza Vaccine Market to 2032 by Vaccine Type, Technology, Age Group, Route of Administration, and Region - GlobeNewswire Inc.
Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - GlobeNewswire Inc.
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts - Benzinga
Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report - GlobeNewswire Inc.
Morgan Stanley cuts Novartis rating amid limited innovation - Baystreet.ca
Market Insight: Novartis AG ADR (NVS)’s Notable Drop, Closing at 118.50 - The Dwinnex
Liver Fibrosis Market Is Expected to Reach USD 43.98 Billion By 2030 - GlobeNewswire Inc.
Regenerative Medicine Market Report 2024 - GlobeNewswire Inc.
Impetigo Drugs Global Strategic Business Report 2024 - GlobeNewswire Inc.
Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology - GlobeNewswire Inc.
Respiratory Drugs - GlobeNewswire Inc.
Chart of the Day: NovartisTake Another Look - TradingView
Cell and Gene Therapy Market Size to Achieve USD 117.46 Bn By 2034 - GlobeNewswire Inc.
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation - TT Nyhetsbyrån
Biologics Market Size to Surge to USD 855.8 Billion by 2031 with a 6.9% CAGR, Fueled by Advanced Targeting of Biological Pathways – Report by Transparency Market Research, Inc. - GlobeNewswire Inc.
By 2034, CAR-T Cell Therapy Market Set to Soar USD 8.7 Billion, at 1.80% CAGR: Prophecy Market Insights - GlobeNewswire Inc.
Multiple Sclerosis (MS) Diagnosis and Treatment Market Size to Reach USD 30.28 Bn by 2032 - GlobeNewswire Inc.
Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - GlobeNewswire Inc.
Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - GlobeNewswire Inc.
Targeted Therapeutics Market is Pioneering Growth Towards a USD 118.6 Billion Milestone by 2031, with a CAGR of 6.4% - GlobeNewswire Inc.
Ex-Chinook team launches Borealis Biosciences with $150-million from Novartis, Versant - The Globe and Mail
Solid Organ Transplant Market is Projected to Grow at a 4.9% CAGR, Reaching $7.88 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.
Strategic Opportunities in Thin Film Drug Manufacturing Market to Expand to USD 16.5 Billion by 2034, Driving Industry Growth | Transparency Market Research Inc. - GlobeNewswire Inc.
UK Patient's Perspective on the Corporate Reputation of Pharma, 2023-2024 - GlobeNewswire Inc.
Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy - Barchart
Cancer Immunotherapy Market Size Expected to Touch USD 530.2 Billion by 2034, With 14.2% CAGR Growth: Prophecy Market Insights - GlobeNewswire Inc.
mTOR (Mammalian Target of Rapamycin) Inhibitors Strategic Research Report 2024: Expanding Applications Beyond Cancer Treatment - GlobeNewswire Inc.
Market Recap Check: Novartis AG ADR (NVS)’s Negative Finish at 113.31, Up/Down -0.19 - The Dwinnex
Is the European Stock Market Too Concentrated? - Morningstar
Monoclonal Antibodies Market Size is Surpassing USD 650.49 Billion by 2033, Growing at Projected 12.0% CAGR - GlobeNewswire Inc.
Why GRANOLAS Performance Has Been So Patchy - Morningstar
Attention-Deficit Hyperactivity Disorder Treatment Market is projected to Reach USD 15.4 Billion, Garnering A 3.1% CAGR from 2024 to 2034 | Report Analysis by Transparency Market Research Inc. - GlobeNewswire Inc.
Active Pharmaceutical Ingredients Market Size Worth $421.56 Billion by 2033: The Brainy Insights - GlobeNewswire Inc.
Antibody Production Market to Surpass USD 36.49 Billion by 2032 Driven by Escalating Demand for Targeted Therapies and Technological Advancements | Research by SNS Insider - GlobeNewswire Inc.
Biotechnology Market Size and Growth | USD 4.25 Trillion by 2033 - GlobeNewswire Inc.
Cervical Spondylosis Diagnosis and Treatment Market Size to Reach USD 6.30 Bn by 2032 - GlobeNewswire Inc.
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss? - Yahoo Canada Finance
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):